The Combination of Panobinostat and Melphalan for the Treatment of Patients with Multiple Myeloma.

Int J Mol Sci · 2022 · PMC9778728 · PMID 36555311

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Interestingly, in both groups of MM patients, combined treatment with panobinostat and melphalan resulted in higher ICL levels at all time points analyzed and increased the ICL burden compared with melphalan-only treatment ( Figure 1 F); however, these results did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.